Drug Database
Back to search

Poland· PL-100489609

Vanflyta

A quizartinib product containing quizartinibum, registered in Poland by Daiichi Sankyo Europe GmbH. The same ATC class is registered in 13 of our 19 countries.

ATC L01EX11

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedVanflytaATCL01EX11REGISTER NO.PL-100489609PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about quizartinibumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Quizartinib is registered in 13 of 19 countries.

Countries holding a registration under ATC L01EX11 (quizartinib), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose
Search quizartinib products by name

Quizartinib · ATC L01EX11

13 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Quizartinibum
Manufacturer
Daiichi Sankyo Europe GmbH
Country
Poland (PL)
ATC code
L01EX11
ATC class
Quizartinib
Defined daily dose
53 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    04260161041458

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Quizartinib in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All quizartinib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Vanflyta
  • Liechtenstein · Vanflyta
  • Norway · Vanflyta

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d91d6cd2-1283-4d69-a101-4a17a565858d
GET /v1/drugs/d91d6cd2-1283-4d69-a101-4a17a565858d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "26,5 mg",
  "packaging": "Rpz ¦ EU/1/23/1768/004 ¦ 151950\n28 tabl.\nRpz ¦ EU/1/23/1768/003 ¦ 151951\n14 tabl.\n04260161041458 ¦ Rpz ¦ EU/1/23/1768/005 ¦ 151952\n56 tabl.",
  "substance": "Quizartinibum 26.5 mg",
  "common_name": "Quizartinibum",
  "pl_product_id": "100489609",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about quizartinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console